Pembrolizumab NEW
Price | $218 | $322 | $542 |
Package | 1mg | 2mg | 5mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Pembrolizumab | CAS No.: 1374853-91-4 |
Purity: 99.70% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Pembrolizumab |
Description | Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family. |
In vitro | METHODS: Peripheral blood mononuclear cells (PBMC) from healthy donors (HD) and primary breast cancer (PBC) were cultured for 24 hours (with plate-bound anti-CD3 and anti-CD28 antibodies for activated cells) and treated with 2 μg/ul Pembrolizumab (MK-3475) treatment (for treated cells) stains intracellular expression of CD4, PD-1 surface marker, and CTLA-4. RESULTS In CD4 T cells, PD-1 expression was significantly higher in PBC patients compared with steady-state HD. Pembrolizumab treatment significantly reduced PD-1 expression in CD4 T cells in both cohorts of non-activated and activated PBMC. [3] METHODS: After HCCLM3 and SK-HEP.1 cells were lysed, 10 ng/mL TNF-α and 10 ng/mL IL-1β were added to the medium of DC and incubated for 48 hours. Finally, DCs were co-cultured with CIK cells at a ratio of 1:10 for 2 days, and on day 12, pembrolizumab 20 ug/mL was added to DC-CIK cells to mediate PD-1 blockade. RESULTS pembrolizumab treatment increased DC-CIK cell proliferation, indicating that pembrolizumab enhanced DC-CIK cell cytotoxicity against HCC cell lines.[4] |
In vivo | METHODS: In the open-label, international, multicenter extension cohort of the phase 1 KEYNOTE-001 trial, patients with advanced melanoma who progressed after 2 or more doses of ipilimumab were randomly assigned to receive 2 mg/kg every 3 weeks or Treatment with Pembrolizumab (MK-3475)10 mg/kg. RESULTS Among the 173 patients treated (2 mg/kg, N = 89; 10 mg/kg, N = 84), the ORR was nearly identical at 26% for both doses, 73% and 68%, respectively. of patients showed reduction in target lesion size. [1] METHODS: Patients were randomly assigned to intravenous pembrolizumab 200 mg every 3 weeks for ≤35 cycles of pembrolizumab or until disease progression, unacceptable toxicity, or discontinuation. Imaging was performed at week 9, then every 6 weeks until year 1, and every 9 weeks thereafter. RESULTS The median OS of pembrolizumab was 14.9 months (95% CI, 11.5-20.6), and it could improve OS in the PD-L1 CPS ≥ 20 and CPS ≥ populations, and the DOR was also significantly longer. [2] |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Keywords | Pembrolizumab | anti-PD-1 |
Inhibitors Related | LSD1-IN-24 | PD-1/PD-L1-IN-9 | Sulfamethoxypyridazine | PD-1-IN-22 | BMS-202 | BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride | IMMH 010 maleate | LSD1-IN-27 | PD-1/PD-L1-IN-10 | BMS-1 | Tomivosertib | PD-L1-IN-3 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/10g |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2023-02-08 | |
$0.00/500MG |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2023-01-17 | |
$0.00/10mg |
Hangzhou Huarong Pharm Co., Ltd.
|
2021-09-15 | ||
$15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
$15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-08 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY